Browsing Blizard Institute by Subject "factor IX"
Now showing items 1-3 of 3
-
Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B.
(Wiley Periodicals, Inc., 2018-11-29)Background: In the phase 3 B-LONG study (NCT01027364), prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) every 7 to >14 days was associated with low annualized bleed rates (ABRs) in males aged ≥12 years ...